Cancer-associated Mutations in SF3B1 Disrupt the Interaction Between SF3B1 and DDX42
Overview
Affiliations
While cancer-associated SF3B1 mutations causes alternative RNA splicing, the molecular mechanism underlying the alternative RNA splicing is not fully elucidated. Here, we analysed the proteins that interacted with the wild-type and K700E-mutated SF3B1 and found that the interactions of two RNA helicases, DDX42 and DDX46, with the mutated SF3B1 were reduced. Overexpression of DDX42 restored the decreased interaction between DDX42 and the K700E-mutated SF3B1, and suppressed some alternative RNA splicing associated with the SF3B1 mutation. Mutation that decreased the ATP hydrolysis activities of DDX42 abolished the suppressive effects of DDX42 on the alternative RNA splicing, suggesting that the ATP hydrolysis activity of DDX42 is involved in the mechanism of the altered RNA splicing associated with the SF3B1 mutation. Our study demonstrates an important function of the interaction between DDX42 and SF3B1 on regulating RNA splicing and revealed a potential role of DDX42 in the altered RNA splicing associated with the SF3B1 mutation.
Damianov A, Lin C, Zhang J, Manley J, Black D bioRxiv. 2024; .
PMID: 39605567 PMC: 11601671. DOI: 10.1101/2024.11.18.624191.
Long-read transcriptome sequencing of CLL and MDS patients uncovers molecular effects of mutations.
Pacholewska A, Lienhard M, Bruggemann M, Hanel H, Bilalli L, Konigs A Genome Res. 2024; 34(11):1832-1848.
PMID: 39271291 PMC: 11610591. DOI: 10.1101/gr.279327.124.
Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease.
Ma J, Ross S Front Immunol. 2024; 15:1451705.
PMID: 39185415 PMC: 11341421. DOI: 10.3389/fimmu.2024.1451705.
GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies.
Benbarche S, Pineda J, Galvis L, Biswas J, Liu B, Wang E Mol Cell. 2024; 84(10):1886-1903.e10.
PMID: 38688280 PMC: 11102302. DOI: 10.1016/j.molcel.2024.04.006.
Boddu P, Gupta A, Roy R, de la Pena Avalos B, Olazabal-Herrero A, Neuenkirchen N Mol Cell. 2024; 84(8):1475-1495.e18.
PMID: 38521065 PMC: 11061666. DOI: 10.1016/j.molcel.2024.02.032.